Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5386-5394

  Kinge, Constance N Wose ^a,b   Espiritu, Christine ^a   Prabdial Sing, Nishi ^c   Sithebe, Nomathamsaqa Patricia ^b   Saeed, Mohsan ^a   Rice, Charles M ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b NORTH WEST UNIVERSITY   (South Africa)

^c NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTIBIOTIC G 418; ANTIVIRUS AGENT; DACLATASVIR; DANOPREVIR; FIREFLY LUCIFERASE; HYBRID PROTEIN; KANAMYCIN KINASE; LEDIPASVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5A; SOFOSBUVIR; VIRUS RNA;

AMINO ACID SUBSTITUTION; ARTICLE; BLOOD DONOR; CELL CLONE; COLONY FORMATION; CONTROLLED STUDY; EVALUATION STUDY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; RNA REPLICATION; SEQUENCE ANALYSIS; SOUTH AFRICA; VIRUS GENOME; VIRUS REPLICATION; CELL LINE; DRUG EFFECTS; GENETICS; HEPACIVIRUS;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CELL LINE; GENOTYPE; HEPACIVIRUS; HUMANS; MUTATION; REPLICON; RNA, VIRAL; VIRUS REPLICATION;

EID: 84906082137     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03534-14     Document Type: Article

References (38)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. 2013. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333-1342. http://dx.doi.org/10. 1002/hep.26141.
2. Poordad F, McCone J, Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 364: 1195-1206. http://dx.doi.org/10. 1056/NEJMoa1010494.
3. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. 2011. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 364:2405-2416. http://dx.doi.org/10.1056/NEJMoa1012912.
4. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. 2013. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368:1878-1887. http://dx.doi.org/10.1056/NEJMoa1214853.
5. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR, POSITRON Study, FUSION Study. 2013. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N. Engl. J. Med. 368:1867-1877. http://dx.doi.org/10.1056/ NEJMoa1214854.
6. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Brau N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators. 2014. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N. Engl. J. Med. 370:1889-1898. http://dx.doi.org/10.1056/NEJMoa1402454.
7. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P, ION-1 Investigators. 2014. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N. Engl. J. Med. 370:1483-1493. http://dx.doi.org/10.1056/NEJMoa1316366.
8. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974. http://dx.doi.org/10.1126/ science.290.5498.1972.
9. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110 -113. http://dx.doi.org/10.1126/science.285.5424.110.
10. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M, Wakita T. 2003. Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817. http://dx.doi.org /10.1053/j.gastro. 2003.09.023.
11. Saeed M, Gondeau C, Hmwe S, Yokokawa H, Date T, Suzuki T, Kato T, Maurel P, Wakita T. 2013. Replication of hepatitis C virus genotype 3a in cultured cells. Gastroenterology 144:56-58 e57. http://dx.doi.org/10.1053/j.gastro.2012. 09.017
12. Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J, Rice CM. 2012. Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells. Antimicrob. Agents Chemother. 56: 5365-5373. http://dx.doi.org/10.1128/AAC.01256-12.
13. Yu M, Peng B, Chan K, Gong R, Yang H, Delaney W, IV, Cheng G. 2014. Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture. Antimicrob. Agents Chemother. 58:2638-2646. http://dx.doi.org/10.1128/AAC.01780-13.
14. Peng B, Yu M, Xu S, Lee YJ, Tian Y, Yang H, Chan K, Mo H, McHutchison J, Delaney W, IV, Cheng G. 2013. Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology 144: 59-61 e56. http://dx.doi.org/10. 1053/j.gastro.2012.09.033
15. Smuts HE, Kannemeyer J. 1995. Genotyping of hepatitis C virus in South Africa. J. Clin. Microbiol. 33:1679-1681.
16. van Doorn LJ, Kleter GE, Stuyver L, Maertens G, Brouwer JT, Schalm SW, Heijtink RA, Quint WG. 1995. Sequence analysis of hepatitis C virus genotypes 1 to 5 reveals multiple novel subtypes in the Benelux countries. J. Gen. Virol. 76(Pt 7):1871-1876. http://dx.doi.org/10.1099/0022-1317-76-7-1871.
17. Jover R, Perez-Serra J, de Vera F, Alamo JM, Munoz C, Yago C, Martinez-Ramirez R, Vidal JV. 2001. Infection by genotype 5a of HCV in a district of southeast Spain. Am. J. Gastroenterol. 96:3042-3043. http://dx.doi.org/10.1111/j.1572-0241.2001.04695.x. (Pubitemid 32959561)
18. Levi JE, Takaoka DT, Garrini RH, Fachini RM, Focaccia R, De Bortholi Santos E, Mitre HP, De Mendonca JS, De Paula Cavalheiro N, Barone AA, Wendel S. 2002. Three cases of infection with hepatitis C virus genotype 5 among Brazilian hepatitis patients. J. Clin. Microbiol. 40:2645-2647. http://dx.doi.org/10. 1128/JCM.40.7.2645-2647.2002. (Pubitemid 34747380)
19. Henquell C, Cartau C, Abergel A, Laurichesse H, Regagnon C, De Champs C, Bailly JL, Peigue-Lafeuille H. 2004. High prevalence of hepatitis C virus type 5 in central France evidenced by a prospective study from 1996 to 2002. J. Clin. Microbiol. 42:3030-3035. http://dx.doi.org/10.1128/JCM.42.7.3030-3035.2004. (Pubitemid 38938053)
20. Bartenschlager R, Lohmann V. 2000. Replication of hepatitis C virus. J. Gen. Virol. 81:1631-1648. (Pubitemid 30427068)
21. Behrens SE, Grassmann CW, Thiel HJ, Meyers G, Tautz N. 1998. Characterization of an autonomous subgenomic pestivirus RNA replicon. J. Virol. 72:2364-2372. (Pubitemid 28100797)
22. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626. http://dx.doi.org/10.1126/science.1114016. (Pubitemid 41033648)
23. Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, Yamashiro T, Nakagawa M, Chen CH, Kanazawa N, Kakinuma S, Watanabe M. 2004. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J. Infect. Dis. 189:1129-1139. http://dx.doi.org/10.1086/382595. (Pubitemid 38457235)
24. Tscherne DM, Evans MJ, von Hahn T, Jones CT, Stamataki Z, McKeating JA, Lindenbach BD, Rice CM. 2007. Superinfection exclusion in cells infected with hepatitis C virus. J. Virol. 81:3693-3703. http://dx.doi.org/10.1128/JVI.01748- 06. (Pubitemid 46586866)
25. Krieger N, Lohmann V, Bartenschlager R. 2001. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J. Virol. 75:4614-4624. http://dx.doi.org/10.1128/JVI.75.10.4614-4624.2001. (Pubitemid 32381503)
26. Lohmann V, Korner F, Dobierzewska A, Bartenschlager R. 2001. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J. Virol. 75:1437-1449. http://dx.doi.org/10.1128/JVI.75.3.1437-1449.2001. (Pubitemid 32094702)
27. Lohmann V, Hoffmann S, Herian U, Penin F, Bartenschlager R. 2003. Viral and cellular determinants of hepatitis C virus RNA replication in cell culture. J. Virol. 77:3007-3019. http://dx.doi.org/10.1128/JVI.77.5.3007-3019.2003. (Pubitemid 36228086)
28. Pineiro D, Martinez-Salas E. 2012. RNA structural elements of hepatitis C virus controlling viral RNA translation and the implications for viral pathogenesis. Viruses 4:2233-2250. http://dx.doi.org/10.3390/v4102233.
29. Prabdial-Sing N, Puren AJ, Mahlangu J, Barrow P, Bowyer SM. 2008. Hepatitis C virus genotypes in two different patient cohorts in Johannesburg, South Africa. Arch. Virol. 153:2049-2058. http://dx.doi.org/10.1007/s00705-008- 0227-2.
30. Bonny C, Fontaine H, Poynard T, Hezode C, Larrey D, Marcellin P, Bourliere M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guillemard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K, Bommelaer G, Abergel A. 2006. Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5: a French multicentre retrospective study. Aliment. Pharmacol. Ther. 24:593-600. http://dx.doi.org/10.1111/j.1365- 2036.2006.03018.x. (Pubitemid 44127840)
31. Wang C, Jia L, O' Boyle DR, II, Sun J-H, Rigat K, Valera L, Nower P, Huang X, Kienzle B, Roberts S, Gao M, Fridell RA. 2014. Comparison of daclatasvir resistance barriers on NS5A from hepatitisCvirus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob. Agents Chemother. 58:5155-5163. http://dx.doi.org/10.1128/AAC.02788-14.
32. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. 2011. Differential efficacy of protease inhibitors againstHCVgenotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 141:1067-1079. http://dx.doi.org/10.1053/j.gastro.2011.06.004.
33. Imhof I, Simmonds P. 2011. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 53:1090-1099. http://dx.doi.org/10.1002/hep.24172.
34. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, Berke JM, Dehertogh P, Fransen E, Scholliers A, Vermeiren K, Ivens T, Raboisson P, Edlund M, Storm S, Vrang L, de Kock H, Fanning GC, Simmen KA. 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob. Agents Chemother. 54: 1878-1887. http://dx.doi.org/10.1128/AAC. 01452-09.
35. Tong X, Bogen S, Chase R, Girijavallabhan V, Guo Z, Njoroge FG, Prongay A, Saksena A, Skelton A, Xia E, Ralston R. 2008. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res. 77:177-185. http://dx.doi.org/10.1016/j.antiviral.2007.11.010.
36. Sarrazin C, Zeuzem S. 2010. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447-462. http://dx.doi.org/10.1053/j.gastro.2009.11.055.
37. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. 2011. RecombinantHCVvariants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology 140:1032-1042. http://dx.doi.org/10.1053/j.gastro.2010.11.036.
38. Nettles RE, Gao M, Bifano M, Chung E, Persson A, Marbury TC, Goldwater R, DeMicco MP, Rodriguez-Torres M, Vutikullird A, Fuentes E, Lawitz E, Lopez-Talavera JC, Grasela DM. 2011. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 54:1956-1965. http://dx.doi.org/10.1002/hep.24609.